Development of field-deployable and point-of-need diagnostics for SARS-CoV-2 using CRISPR-based technology

Pickering, Bradley | $411,820

Manitoba Canadian Science Centre for Human and Animal Health 2020 CIHR Operating Grant

Current diagnostic testing for the SARS-CoV-2 outbreak requires the use of specialized equipment for molecular-based pathogen detection. The equipment must be housed in a facility with electricity and freezers for storage of temperature sensitive materials and equipment operation. Lateral flow based assays are an alternative diagnostic tool that is inexpensive, temperature stable, user-friendly and has a faster turn-around-time (TAT). However, this platform takes longer to develop, with reduced specificity, sensitivity, and accuracy compared to molecular-based assays. An ideal diagnostic tool combines the adaptability and reliability of molecular assays with the TAT, cost-effectiveness, and stability of lateral flow. Clustered Regularly Interspersed Short Palindromic Repeats (CRISPR) based diagnostics can provide these capabilities and revolutionize the field of point-of-need molecular-based diagnostics. Our goal is to develop CRISPR-based diagnostics to detect SARS-CoV-2 at the point-of-need, such as at the bedside, passenger screening, or returning travellers who may have been exposed. We recently demonstrated that CRISPR-based diagnostics is reliable, sensitive and can be used to detect Ebola virus and Crimean-Congo hemorrhagic fever virus. SARS-CoV-2 is highly contagious and caused more than 69,000 infections and contributed to over 1600 deaths. Therefore, it is of utmost importance to quickly diagnose SARS-CoV-2 infection to administer appropriate patient care and isolation. CRISPR-based diagnostics is a next-generation diagnostic tool that can provide results in a timely manner and fill this gap. Implementation of CRISPR-based diagnostics will complement our armamentarium against high-consequence pathogens and will address the need for faster, cheaper, and more robust diagnostics for emerging infectious diseases of public health concern.

With funding from the Government of Canada

Please complete this short survey to help us understand our impact. Thank you!

Give Feedback